Litcius/Paper detail

Prognostic Value of Tumor Volume Assessment on PSMA PET After<sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0

Felix Kind, Ann-Christin Eder, Cordula A. Jilg, Philipp E. Hartrampf, Philipp T. Meyer, Juri Ruf, Kerstin Michalski

2022Journal of Nuclear Medicine31 citationsDOIOpen Access PDF

Abstract

Quantitative evaluation of prostate-specific membrane antigen (PSMA)–targeting PET/CT remains challenging but is urgently needed for the use of standardized PET-based response criteria, such as the PSMA PET/CT consensus statement or Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0). A recent study evaluated the prognostic value of whole-body tumor volume using a semiautomatic method relying on a 50% threshold of lesion SUV<sub>max</sub> (PSMA<sub>TV50</sub>). In the present study, we analyzed the suitability of this approach comparing <sup>18</sup>F-PSMA-1007 with <sup>68</sup>Ga-PSMA-11 PET/CT scans and the potential of PSMA<sub>TV50</sub> for the prediction of overall survival (OS) in patients before <sup>177</sup>Lu-PSMA radioligand therapy (RLT). Moreover, PSMA<sub>TV50</sub> was integrated into the PSMA PET/CT consensus statement as well as RECIP 1.0, and the prognostic value of these response classification systems was compared. <b>Methods:</b> This retrospective study included 70 patients with metastatic castration-resistant prostate cancer undergoing PSMA RLT. Thirty-three patients were monitored by <sup>68</sup>Ga-PSMA-11 PET/CT, and 37 patients by <sup>18</sup>F-PSMA-1007 PET/CT. PET/CT scans before (baseline) and at the end of PSMA RLT after 2–4 cycles (follow-up) were separately analyzed by 2 readers. PSMA<sub>TV50</sub> at baseline and its change at the time of follow-up (ΔPSMA<sub>TV50</sub>, expressed as a ratio) were correlated with OS using Cox proportional-hazards regression. The results of both subgroups were compared. The integration of ΔPSMA<sub>TV50</sub> in existing response classification systems was evaluated. To assess and compare the discriminatory strength of these classification systems, Gönen and Heller concordance probability estimates were calculated. <b>Results:</b> PSMA<sub>TV50</sub> determination was technically feasible in all examinations. A higher PSMA<sub>TV50</sub> at baseline and a higher ΔPSMA<sub>TV50</sub> were strongly associated with a shorter OS for both <sup>68</sup>Ga-PSMA-11 (PSMA<sub>TV50</sub>: hazard ratio [HR] of 1.29 [95% CI, 1.05–1.55], <i>P</i> = 0.009; ΔPSMA<sub>TV50</sub>: HR of 1.83 [95% CI, 1.08–3.09], <i>P</i> = 0.024) and <sup>18</sup>F-PSMA-1007 (PSMA<sub>TV50</sub>: HR of 1.84 [95% CI, 1.13–2.99], <i>P</i> = 0.014; ΔPSMA<sub>TV50</sub>: HR of 1.23 [95% CI, 1.04–1.51], <i>P</i> = 0.03). Response assessment provided high discriminatory power for OS for the PSMA PET/CT consensus statement (concordance probability estimate, 0.73) as well as RECIP 1.0 (concordance probability estimate, 0.74). <b>Conclusion:</b> PSMA<sub>TV50</sub> and ΔPSMA<sub>TV50</sub> proved to be predictive of OS not only for <sup>68</sup>Ga-PSMA-11 but also for <sup>18</sup>F-PSMA-1007 PET/CT scans. Subsequent integration of ΔPSMA<sub>TV50</sub> into the PSMA PET/CT consensus statement and RECIP 1.0 provided equally high prognostic value for both classification systems.

Topics & Concepts

MedicineRadioligandProstate cancerNuclear medicineGlutamate carboxypeptidase IIPET-CTPositron emission tomographyStandardized uptake valueProportional hazards modelOncologyInternal medicineCancerReceptorProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsCancer, Lipids, and Metabolism
Prognostic Value of Tumor Volume Assessment on PSMA PET After<sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0 | Litcius